We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
-13.32%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$2.5B
AUM Growth
-$255M
Cap. Flow
+$290M
Cap. Flow %
11.6%
Top 10 Hldgs %
45.64%
Holding
89
New
6
Increased
32
Reduced
5
Closed
8

Top Buys

Rank Stock Value
1
ITOS
iTeos Therapeutics
ITOS
+$50.9M
2
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$35.6M
3
RLAY icon
Relay Therapeutics
RLAY
+$34M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$31.1M
5
ARGX icon
argenx
ARGX
+$29.1M

Top Sells

Rank Stock Value
1
AMRN
Amarin Corp
AMRN
+$55.5M
2
XENE icon
Xenon Pharmaceuticals
XENE
+$50.6M
3
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$29.4M
4
MIRM icon
Mirum Pharmaceuticals
MIRM
+$6.95M
5
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$6.74M

Sector Composition

Rank Sector Weight
1 Healthcare 99.31%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RNAC icon
76
Cartesian Therapeutics
RNAC
$222M
$2.12M 0.08%
57,438
– –
XFOR icon
77
X4 Pharmaceuticals
XFOR
$372M
$1.48M 0.06%
28,263
– –
ABOS icon
78
Acumen Pharmaceuticals
ABOS
$155M
$1.13M 0.05%
289,663
– –
JNCE
79
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$861K 0.03%
+126,797
New +$904K
NEUP
80
Neuphoria Therapeutics
NEUP
$21.5M
$692K 0.03%
6,748
– –
RZLT icon
81
Rezolute
RZLT
$449M
$645K 0.03%
190,815
– –
AMRN
82
Amarin Corp
AMRN
$295M
– –
-822,998
Closed -$55.5M
MIRM icon
83
Mirum Pharmaceuticals
MIRM
$6.58B
– –
-435,936
Closed -$6.95M
KDNY
84
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
– –
-1,800,000
Closed -$29.4M
EUCRU
85
DELISTED
Eucrates Biomedical Acquisition Corp. Unit
EUCRU
– –
-500,000
Closed -$4.99M
RACB
86
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
– –
-500,000
Closed -$4.86M
JYAC
87
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
– –
-300,000
Closed -$2.93M
FLACU
88
DELISTED
Frazier Lifesciences Acquisition Corporation Unit
FLACU
– –
-500,000
Closed -$4.95M
FVAM
89
DELISTED
5:01 Acquisition Corp
FVAM
– –
-500,000
Closed -$4.92M
1 2 3
4

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q1 2022 Portfolio in Review

As of Q1 2022, BVF Inc held 89 positions worth $2.5B, down 9.3% from $2.76B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

BVF Inc deployed $290M of net new capital in Q1 2022, opening 6 new positions and adding to 32 existing holdings. Its largest new stake was iTeos Therapeutics: 1,400,201 shares worth $45.1M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Xenon Pharmaceuticals, an estimated $50.6M trimmed.

  • BVF Inc's largest Q1 2022 buy was iTeos Therapeutics: 1,400,201 shares worth $45.1M.
  • BVF Inc added most to Relay Therapeutics in Q1 2022, an estimated $34M increase.
  • BVF Inc's biggest Q1 2022 reduction was Xenon Pharmaceuticals, cutting an estimated $50.6M.
  • BVF Inc fully exited Amarin Corp in Q1 2022, selling an estimated $55.5M.
  • BVF Inc's ten largest holdings make up 46% of its $2.5B portfolio in Q1 2022.
  • BVF Inc opened 6 new positions and closed 8 in Q1 2022.
  • BVF Inc's portfolio value fell 9.3% quarter-over-quarter to $2.5B.

Based on BVF Inc's 13F filing for Q1 2022, filed 16 May 2022.